Krystal Biotech is trading at $347.76 (-5.20%) following a sharp intraday drop that appears driven by broader industry trends rather than company-specific news.
- The move is consistent with a wider sell-off in the biotechnology space, with the XBI sector ETF down 3.15% in the current session.
- The decline occurs alongside mixed U.S. market performance and a general risk-off tone impacting several high-growth areas.